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In situations where the gastric is injured  by  
hyperacidity,  epithelial  cells  or  
submucosal cells produced growth factors 
that stimulate cell proliferation and repair 
the gastric injury.  The growth factors 
known as the basic fibroblast growth factor 
(bFGF) and epidermal growth factor (EGF) 
have been recognized to promote ulcer 
healing (Szabo et al., 1995). 
Fucoidan is a complex sulfated 
polysaccharide, derived from marine brown 
algae (Nishino et al., 1991a). Fucoidan is also 
an acid polysaccharide characterized by the 
main constituents of fucose and sulfate 
radical and galactose, xylose or uronic acid  
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Abstract
Hyperacidity causes gastric injury, and in severe situations, ulcer could develop. The growth factors known as 
the basic fibroblast growth factor (bFGF) and the epidermal growth factor (EGF) have been recognized to promote 
ulcer healing. Fucoidan is extracted from a brown seaweed of Okinawa called Mozuku or Cladosiphon okamuranus. 
Fucoidan is effective for the healing of gastric ulcers by inducing epithelial cells to produce growth factors.  The aim 
of this study is to explore the efficacy of fucoidan in patient who suffered by gastric ulcer. A randomized control trial 
double blind was conducted to 33 eligible samples. By using four-blocks random samples were divided into fucoidan 
and placebo groups. 100 mg of fucoidan was given to the fucoidan group and 100 mg of glucose was given to the 
placebo group.  Due to ethical reasons, for both groups were given a proton pump inhibitor. There was no difference 
in the age category between the fucoidan group (mean: 46.23 ± 14.8 years) and the placebo group (mean: 46.18 ± 18.4 
years) (p: 0.28). There was also no difference in sex between the fucoidan group (female: 10/33; male 7/33) and the 
placebo group (female: 7/33; male: 9/33); p: 0.38. According to the SAKITA and MIWA criterias 32 patients fulfilled 
A1 which indicate active severe ulcer, and 1 patient fulfilled A2 which indicate active moderate ulcer. Most of the 
ulcers were gastric ulcer. There was a significant improvement of the grade of ulcer in fucoidan group (94%) (16/17) 
compared to placebo group (37.5%) (6/16,p: 0.005). There was a significant reduction of abdominal pain after 5 days 
in the fucoidan group, compared to the placebo group (p: 0.04). Vomiting tends to decrease in day 6 of the fucoidan 
group however its proportion is similar with that of the placebo group (p: 0.9). Fucoidan is effective for ulcer healing 
and reducing ulcer symptoms. 
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Introduction
Gastric epithelial cells secreted a 
proteoglycan ca l led  mucin  which  
protectsthe gastric mucosa from acid and 
pepsin. Sulfated polysaccharides as known 
as sulfomucins are reported to exert 
antipeptic activity by ionic binding of gastric 
surface proteins (Takagaki and Hota, 1979). 
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is  contained  as constituent  sugar  de-
pending on the seaweed species (Berteau et 
al., 2003).
 The fucoidans from brown seaweed 
mediate a variety of significant biological 
effects on mammalian cells and have many 
biological activities such as anticoagulant 
(Bernardi and Springer, 1962), activators 
antithrombin III and heparin cofactor 
(Nishino et al., 1991b), inhibit  initial binding 
of sperm for penetration of the human 
pellucida zone (Mahoni et al., 1991), blocks 
the infection of human cells line in several 
v i ra l  in fec t ion ,  HIV,  herpes  and  
cytomegalovirus, and cells binding, and also 
demonstrates differential binding of some 
inflammatory mediators (Foxall et al., 1992). 
In particular, fucoidan is effective for ulcer 
healing of gastric ulcers. Some studies 
demonstrate anti ulcer effect of fucoidan by 
induce epithelial cells to produce growth 
factors  (Szabo et al., 1995). 
In the present study, we therefore 
explore the efficacy of fucoidan in patients 
who suffered from gastric ulcer.
Subjects and Methods
The subjects of this study are patients 
who attended to the out patients or in 
p a t i e n t s  i n  t h e  s u b d i v i s i o n  o f  
Gastroenterology, Pediatrics Department 
and the Department of Internal Medicine, 
Sardjito Hospital, Yogyakarta; Hasan 
Sadikin Hospital Bandung and Syaiful 
Anwar Hospital, Malang, Indonesia during 
2004-2006. The inclusion criteria are patients 
with the age of at least eight years with 
abdominal pain or dyspepsia according to 
the dyspepsia criteria scale, and during the 
last month did not consumed any anti ulcer 
drugs.  
All patients who fulfilled the criteria 
underwent a first endoscope.  In the first 
endoscope the patients who had ulcer were 
included in the study and patients who had 
Helicobacter Pylori infection and gastric 
cancer were excluded from the study.  The 
subjects agreed to be involved in the study 
by signing an informed consent.  Ethical 
Clearance was adjusted by the Medical Ethic 
Committee from the Faculty of Medicine, 
Padjad jaran Univers i ty ,  Bandung,  
Indonesia.  Patients eligible for the study 
were randomly allocated using four-steps 
block random, and then they were divided 
into the fucoidan group and placebo group.  
After three weeks of receiving fucoidan or 
placebo, the patients underwent a second 
endoscope to evaluate the ulcer.  Biopsies of 
gastric and duodenal mucosa were obtained 
during endoscopes and specimens were sent 
to the pathologist.  The severity of the ulcer 
was diagnosed referring to the SAKITA and 
MIWA criteria (Takemoto et al., 1991) as 
shown in Table 1.
Table 1.   Sakita and Miwa classification
The fucoidan group received 100 mg of 
fucoidan a day for three weeks.  This 
fucoidan is extracted from the Okinawa 
brown seaweed called Mozuku or 
Cladosiphon Okamuranus.  The structure of 
the fucoidan is  a  high molecular 
polysaccharide on a base unit of fucose, part 
of which is bounded to uronic acid.  
The placebo group received placebo 
which consist of glucose.  The fucoidan and 
placebo were packed into a capsule in the 
same size and same color.  A proton 
pumpinhibitor was given to fucoidan and 
placebo group for ethical reason. During the 
three weeks, patients consumed the 
fucoidan and placebo; they were followed 
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up regarding clinical symptoms and signs 
according to the case report form.  All data 
were  analyzed using  computer analyzing 
program SPSS version 12.  The difference 
between fucoidan and placebo group was 
calculated using the chi-square analysis 
program for proportional data.  The 
difference between the means was 
calculated using a student t test analyzing 
program.   
Results
Thirty three samples were 
included in the study, 17 patients were in the 
fucoidan group and 16 patients were in the 
placebo group (p: 1).  Distended in days 4 
tended to decrease in fucoidan group.  There 
was no difference in age category between 
fucoidan group (mean: 46.23 ± 14.8 years) 
and placebo group (mean: 46.18 ± 18.4 years) 
(p: 0.28) (Table 2).  There was no difference in 
the gender category between fucoidan 
group (female: 10/33; male 7/33) and 
placebo group (female: 7/33; male: 9/33); p: 
0.38 (Table 3).
Table 2.  Age distribution
 
Table 3.  Sex distribution
Table 4.  Diagnosis of ulcer according to SAKITA and 
MIWA before treatment
According to the SAKITA and MIWA 
criteria 32 patients fulfilled A1 category, 
which indicate active severe ulcer, and one 
patient fulfilled A2 which indicate active 
moderate ulcer (Table 4, Figure 1).  Most of 
the ulcers are gastric ulcer. There was 
significant improvement of grade of the 
ulcer in the fucoidan group 94% (16/17) 
compareto the placebo group 37.5% (6/16) 
Table 5, Figure 2. (p: 0.005). 
Figure 1.  Bar chart of diagnosis ulcer before treatment
Table 5.  Diagnosis of ulcer after treatment
Figure 2.  The diagnosis of ulcer acording to Sakita 
and Miwa after treatment 
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Group         Sex
 
Female    Male  
      Total
 
   P
Fucoidan  
Placebo
10 7  
   7              9
       17  
        16
0.38
Group         Sex
 
Female    Male  
      Total
 
   P
Fucoidan  
Placebo
10 7  
   7              9
       17  
        16
0.38
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There was significant reduction of 
abdominal pain after five days in the 
fucoidan group compared to the placebo 
group (p: 0.04; Figure 3).  In addition, 
vomiting tends to decrease in days 6 in the 
fucoidan group (Figure 4). However, its the 
proportion is similar with that in placebo 
group ( p: 0.9). Distended was significant 
decreased in days 3 in the fucoidan group, 
compared to that in the placebo group (p: 
0.02, Figure 5).
   
Figure 3. Abdominal pains after 5 days observation              
 
        
Figure 4. Vormiting after 6 days observation       
          
Figure 5. Distended after 5 days observation 
Discussion
This study explored the efficacy of 
fucoidan in gastric ulcer.  Fucoidan 
significantly have effects ulcer healing, 
compared to those in without fucoidan.  The 
symptoms of dyspepsia were reduced 
significantly after days 5-6 days of 
consuming fucoidan. Incidence of gastric 
ulcer is only slightly higher among men and 
around 5% to 10% of the population  (Soll, 
1989).
In acute gastritis there is erosion and 
damage to the gastric mucosa.  If the erosion 
is deep and this damage is distributed in 
focal area through the mucosa and in some 
cases through the submucosa then gastric 
ulcer could occur.  The damage generally 
occur in the setting of a serious systemic 
illness such as trauma, burns, sepsis, liver 
and renal failures and shock, or with certain 
drugs such as non-steroid anti inflammatory 
drugs (Soll, 1990). 
This study showed that most of the 
patients (94%) with severe gastric ulcers 
(active stage) who received fucoidan 100 mg 
a day for three weeks changed to the healing 
stage or scarring stage.  In contrast, patients 
who receive placebo only 37.5% changed to 
the healing stage.  This indicates that 
fucoidan is strongly has anti gastric ulcer 
effects.
F u c o i d a n  f r o m  C l a d o s i p h o n  
Okamuranus is known to have anti ulcer 
effects.  Some studies have demonstrated 
that fucoidan has anti-ulcer effects.  Using 
acetic acid induced gastric ulcer and 
indomethacin induced gastric erosion 
models in rat (Shibata et al., 1998), it was 
suggested that  the fucoidan from 
Cladosiphon binds proteins, inhibits 
peptides activity and prevent the bFGF 
instability, which should results in an anti-
ulcer effect.  In agreement herewith, a study 
using hemoglobin and BSA as substrate 
demonstrated that  fucoidan f rom 
Cladosiphon Okamuranus is a sulfated 
polysaccharide with a potent anti-ulcer 
activity by preventing peptic digestions 
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(Shibata et al., 2000).  The anti-peptic effects 
of sulfate polysaccharide were due to their 
anionic change and to the ionic binding to 
the protein substrate.  The lackof inhibition 
with a low molecular weight synthetic 
s u b s t r a t e  N - a c e t y l p h e n y l a l a n y l  
diiodotyrosine showed that the effect is not 
on the enzyme itself (Shibata et al., 2000).
In addition, Cladosiphon fucoidan does 
not stimulate superoxide generation and 
TNFá secretion by inflammatory cells.  It 
means that Cladosiphon fucoidan did not 
show any inflammatory effect (Shibata et al., 
2000).In concern with gastric mucosal 
protection, Cladosiphon fucoidan has an 
effect on the bFGF stabilizing activity 
(Folkman et al., 1991; Ornitz et al., 1995; 
Chintala et al., 1994; Faham et al., 1996; 
Shibata et al., 2000). The studies showed that 
this sulfated polysaccharides stabilize bFGF 
by binding to the peptide. The stabilized 
bFGF activity work on the pH 7.4 and pH 4.0 
(Shibata et al., 2000). As a study in patients 
who had gastric ulcer, this study proved that 
all effect of fucoidan occur in the patient.  
This study also showed that the clinical 
symptoms of gastric ulcer, abdominal 
pain,vomiting and abdominal distended 
were reduced 3-4 days after receiving 
fucoidan Cladosiphon.  These observations 
reflected on the correlation between effects 
of ulcer healing towards the clinical 
symptoms of the gastric ulcer. 
Conclusion  
Cladosiphon fucoidan has an effect on 
anti-ulcer in patients with gastric ulcer.
Acknowledgment
The authors would like to thank Meiji 
Seika Kaisha Ltd and Toyo Science 
Corporation for supporting writing this 
paper.
References 
Bernardi, G., and Springer, G.F., 1962, 
Properties of highly purified fucan. J. 
Biol. Chem., 237, 75–80.
Berteau, O., and Mulloy, B., 2003, Sulfated 
fucans, fresh perspectives: structures, 
functions, and biological properties of 
sulfated fucans and an overview of 
enzymes active toward this class of       
polysaccharide. Glycobiology,  13 (6), 
29R-40R.
Chintala, S.K., Millar, R.R., and McDevitt, 
C.A., 1994, Basic fibroblast growth 
factor binds to heparin sulfate in the 
extracellular matrix of rat growth plate 
chondrocytes. Arch. Biochem. Biophys.  
310, 180-186.
Faham, S., Hileman, R.E., Fromm, J.R., 
Linhardt, R.J., and Rees, D.C., 1996, 
Heparin structure and interactions 
with basic fibroblast growth factor. 
Science, 271, 1116-1120.
Folkman, J., Szabo, S., Stovroff, M., McNeil, 
P., Li, W., and Shing, Y., 1991, 
Duodenal ulcer. Discovery of a new 
mechanism and development of 
angiogenic therapy that accelerates 
healin. Ann. Surg., 214, 414-427.
Foxall, C., Watson, S.R., Dowbenko, D., 
Fennie,  C.,  Lasky,  L. A.,   Kiso,  M.,
Hasegawa, A., Asa, D., and Brandley, B.K., 
1992, The three members of the selectin 
receptor family recognize a common 
carbohydrate epitope, the sialyl 
Lewis(x) oligosaccharide. J. Cell. Biol., 
117 (4), 895–902.
Mahony, M.C., Oehninger, S., Clark, G.F, 
Acosta, A.A., and Hodgen, G.D., 1991, 
Contraception, 44, 657-665.
Nishino, T., Kiyohara, H., Yamada, H., and 
Nagumo, T., 1991a, An anticoagulant 
fucoidan from the brown seaweed 
Ecklonia kurome. Phytochemistry, 30, 
535-539.
Nishino, T., Aizu, Y., and Nagumo, T., 1991b, 
Antithrombin activity of a fucan 
sulfate from the brown seaweed 
Juffrie et al.                                                                                                                                            I.J. Biotech.
913
Ecklonia kurome. Thromb. Res.,  62(6), 
765-773. 
Ornitz, D.M., Herr, A.B., Nilsson, M., 
Westman, J., Svahn, C.M., and 
Waksman, 1995, FGF binding and FGF 
receptor activation by synthetic 
h e p a r i n - d e r i v e d  d i -  a n d  t r i  
saccharides. Science, 268, 432-436.
Shibata, H., Nagaoka, M., Takeuchi, Y., 
Hashimoto, S., Ueyama, S., and 
Yokokura, T., 1998, Anti-ulcer effect of 
fucoidan from brown seaweed, 
Cladosiphon okamuranus tokida. Jpn. 
Pharmacol. Ther., 26, 1211-1215.
Shibata, H., Takagi, I.K., Nagaoka, M., 
Hashimoto, S., Aiyama, R., Iha, M., 
Ueyama, S., and Yokokura, T., 2000, 
P r o p e r t i e s  o f  f u c o i d a n  f r o m  
Cladosiphon okamuranus tokida in 
gastric mucosal protection. Bio Factors, 
11, 235-245.
Soll, AH., 1989, Duodenal ulcer and drug 
therapy. In: Sleisenger M.H., and 
Fordtran, J.S., eds. Gastrointestinal 
disease: pathophysiology, diagnosis, 
management. 4th ed. Philadelphia: 
Saunders, 814-879
Soll, A.H., 1990,  Pathogenesis of peptic ulcer 
and implications for therapy. N. Engl. J. 
Med., 322, 909-916.
Szabo, S., Kusstatscher, S., Sander, Z., and 
Sakoulas, G., 1995, Molecular and 
cellular basis of ulcer healing. Scand. 
J.Gastroenterol., 30. Suppl. 208, 3-8.
Takagaki, Y.M., and Hota, K., 1979, 
Characterization of peptic inhibitory 
activity associated with sulfates 
glycoprotein   isolated  from    gastric 
mucosa. Biochem. Biophys. Acta, 584, 
288-297.
Takemoto, T., Sasaki, N., Tada, M., Yanai, H., 
and Okita, K., 1991, Evaluation of 
peptic ulcer healing with a highly 
magnifying endoscope: potential 
p r o g n o s t i c  a n d  t h e r a p e u t i c  
implications. J. Clin. Gastroenterol.,  13 
(Suppl 1), S125-128.
Juffrie et al.                                                                                                                                            I.J. Biotech.
